Ligand validation:2NY5

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 2NY5 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2NY5_NAG_G_762	81%	58%	0.114	0.965	0.62	0.97	-	-	0	0	100%	0.9333
2NY5_NAG_G_789	73%	58%	0.134	0.961	0.53	1.07	-	3	0	0	100%	0.9333
2NY5_NAG_G_795	68%	61%	0.141	0.952	0.54	0.94	-	-	1	0	100%	0.9333
2NY5_NAG_G_948	55%	55%	0.166	0.935	0.55	1.16	-	1	0	0	100%	0.9333
2NY5_NAG_G_886	53%	63%	0.14	0.899	0.53	0.89	-	1	1	0	100%	0.9333
2NY5_NAG_G_776	51%	63%	0.146	0.899	0.47	0.95	-	1	0	0	100%	0.9333
2NY5_NAG_G_734	11%	55%	0.276	0.8	0.64	1.09	-	2	0	0	100%	0.9333
2NY5_NAG_G_839	11%	45%	0.251	0.763	0.62	1.47	-	4	0	0	100%	0.9333
2NY5_NAG_G_892	4%	55%	0.373	0.756	0.55	1.17	-	2	1	0	100%	0.9333
3IDX_NAG_G_886	90%	58%	0.091	0.972	0.63	0.96	-	-	0	0	100%	0.9333
2NY6_NAG_A_762	84%	49%	0.114	0.976	0.68	1.27	-	2	0	0	100%	0.9333
2NY0_NAG_A_762	79%	58%	0.123	0.968	0.54	1.06	-	1	0	0	100%	0.9333
2NY7_NAG_G_886	77%	63%	0.114	0.953	0.27	1.13	-	3	0	0	100%	0.9333
2NY4_NAG_A_776	69%	66%	0.113	0.926	0.57	0.75	-	-	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333
5O59_NAG_A_601	100%	70%	0.024	0.993	0.3	0.85	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.